ZA956005B - Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes - Google Patents

Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes

Info

Publication number
ZA956005B
ZA956005B ZA956005A ZA956005A ZA956005B ZA 956005 B ZA956005 B ZA 956005B ZA 956005 A ZA956005 A ZA 956005A ZA 956005 A ZA956005 A ZA 956005A ZA 956005 B ZA956005 B ZA 956005B
Authority
ZA
South Africa
Prior art keywords
diagnostic
iron
production
therapeutic purposes
containing nanoparticles
Prior art date
Application number
ZA956005A
Other languages
English (en)
Inventor
Mayk Kresse
Detle Dr Pfefferer
Reudiger Dr Lawaczek
Susanne Dr Wagner
Wolfgang Dr Ebert
Volker Elste
Wolfhard Dr Semmler
Matthias Dr Taupitz
Josef Gaida
Anja Herrmann
Monika Jukl
Udo Swiderski
Original Assignee
Diagnostikforschung Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diagnostikforschung Inst filed Critical Diagnostikforschung Inst
Publication of ZA956005B publication Critical patent/ZA956005B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1866—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle the nanoparticle having a (super)(para)magnetic core coated or functionalised with a peptide, e.g. protein, polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/14—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar alpha-D-Glucans, i.e. having alpha 1,n (n=3,4,6) linkages between saccharide units, e.g. pullulan
    • G01N2400/22—Dextran
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/20—Magnetic particle immunoreagent carriers the magnetic material being present in the particle core
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2446/00—Magnetic particle immunoreagent carriers
    • G01N2446/30—Magnetic particle immunoreagent carriers the magnetic material being dispersed in the polymer composition before their conversion into particulate form

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA956005A 1994-08-04 1995-07-19 Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes ZA956005B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4428851A DE4428851C2 (de) 1994-08-04 1994-08-04 Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie

Publications (1)

Publication Number Publication Date
ZA956005B true ZA956005B (en) 1996-02-22

Family

ID=6525704

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA956005A ZA956005B (en) 1994-08-04 1995-07-19 Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes

Country Status (13)

Country Link
US (3) US6048515A (ko)
EP (1) EP0773796A1 (ko)
JP (1) JPH10503496A (ko)
KR (1) KR100278513B1 (ko)
CN (1) CN1103604C (ko)
AU (1) AU703042B2 (ko)
CA (1) CA2195318C (ko)
DE (1) DE4428851C2 (ko)
HU (1) HUT77993A (ko)
IL (1) IL114713A (ko)
NO (1) NO314785B1 (ko)
WO (1) WO1996004017A1 (ko)
ZA (1) ZA956005B (ko)

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie
US5855868A (en) * 1996-04-01 1999-01-05 Nycomed Imaging As Method of T1 -weighted resonance imaging of RES organs
DE59706019D1 (de) * 1996-08-05 2002-02-21 Schering Ag Vorrichtung und verfahren zur abtrennung magnetischer materialien aus pharmazeutischen zubereitungen, deren ausgangs- oder zwischenprodukten sowie mit hilfe dieser vorrichtung hergestellte mittel
FR2753902B1 (fr) * 1996-09-27 1999-04-02 Ioualalen Karim Nouveau type de matrice ionique biodegradable de polarite interne modulable a polymere greffe
DE19652374A1 (de) * 1996-12-04 1998-06-10 Schering Ag Verwendung von Endothelin-Konjugaten in der Therapie, neue Endothelin-Konjugate, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
ATE250895T1 (de) * 1997-02-26 2003-10-15 Zeiss Carl Meditec Ag Marker zur bestimmung seiner position in einem hohlraum innerhalb des organismus eines lebewesens
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
CA2335951C (en) * 1998-06-24 2013-07-30 Mark S. Chee Decoding of array sensors with microspheres
US6470220B1 (en) * 1999-03-29 2002-10-22 The Regents Of The University Of California Diagnosis and treatment of cancers using in vivo magnetic domains
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6544732B1 (en) * 1999-05-20 2003-04-08 Illumina, Inc. Encoding and decoding of array sensors utilizing nanocrystals
AU4305101A (en) * 1999-11-22 2001-06-04 Research Foundation Of The State University Of New York, The Magnetic nanoparticles for selective therapy
US6530944B2 (en) 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
EP1264181B1 (en) 2000-03-06 2007-06-06 Dade Behring Marburg GmbH Carriers coated with polysaccharides, their preparation and use
US7537938B2 (en) * 2000-04-28 2009-05-26 Monogram Biosciences, Inc. Biomarker detection in circulating cells
PL366025A1 (en) * 2000-05-03 2005-01-24 Munich Biotech Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2001091808A2 (en) * 2000-06-01 2001-12-06 The Board Of Regents For Oklahoma State University Bioconjugates of nanoparticles as radiopharmaceuticals
US20050013775A1 (en) * 2000-06-01 2005-01-20 Kotov Nicholas A. Bioconjugates of nanoparticles as radiopharmaceuticals
US6690962B2 (en) * 2000-09-15 2004-02-10 Institut fur Diagnostikforshung GmbH Process for graphic visualization and diagnosis of thrombi by means of nuclear spin tomography with use of particulate contrast media
AU2002256602B2 (en) * 2001-03-08 2005-06-09 Centrum Fur Angewandte Nanotechnologie (Can) Gmbh Paramagnetic nanoparticle
US7081489B2 (en) * 2001-08-09 2006-07-25 Florida State University Research Foundation Polymeric encapsulation of nanoparticles
DE10154016B4 (de) * 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
US20030219785A1 (en) * 2002-02-01 2003-11-27 Vanderbilt University Targeted drug delivery methods
US20030185757A1 (en) * 2002-03-27 2003-10-02 Mayk Kresse Iron-containing nanoparticles with double coating and their use in diagnosis and therapy
WO2003086660A1 (en) * 2002-04-09 2003-10-23 The Government Of The United States Of America As Represented By The Secretary Of The Navy Magnetic nanoparticles having passivated metallic cores
US6962685B2 (en) * 2002-04-17 2005-11-08 International Business Machines Corporation Synthesis of magnetite nanoparticles and the process of forming Fe-based nanomaterials
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
AU2003259846A1 (en) * 2002-08-16 2004-03-03 The General Hospital Corporation Non-invasive functional imaging of peripheral nervous system activation in humans and animals
US20040058457A1 (en) * 2002-08-29 2004-03-25 Xueying Huang Functionalized nanoparticles
US20050064508A1 (en) * 2003-09-22 2005-03-24 Semzyme Peptide mediated synthesis of metallic and magnetic materials
US6989196B2 (en) * 2002-10-02 2006-01-24 Florida State University Research Foundation Microencapsulation of magnetic material using heat stabilization
US7459145B2 (en) * 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
GB0227738D0 (en) * 2002-11-28 2003-01-08 Univ Liverpool Nanoparticle conjugates and method of production thereof
AU2003900335A0 (en) * 2003-01-22 2003-02-13 Sirtex Medical Limited Microparticles for selectively targeted hyperthermia
DE10331439B3 (de) * 2003-07-10 2005-02-03 Micromod Partikeltechnologie Gmbh Magnetische Nanopartikel mit verbesserten Magneteigenschaften
US7235228B2 (en) * 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20070003975A1 (en) * 2003-05-02 2007-01-04 Canon Kabushiki Kaisha Structured construct and producing method therefor
KR100936269B1 (ko) * 2003-06-07 2010-01-12 연세대학교 산학협력단 자성체-고분자 입자 및 그의 제조방법
US7723311B2 (en) * 2003-06-18 2010-05-25 Nanobiomagnetics, Inc. Delivery of bioactive substances to target cells
US8651113B2 (en) * 2003-06-18 2014-02-18 Swr&D Inc. Magnetically responsive nanoparticle therapeutic constructs and methods of making and using
US7344491B1 (en) 2003-11-26 2008-03-18 Nanobiomagnetics, Inc. Method and apparatus for improving hearing
WO2005002643A2 (en) * 2003-06-24 2005-01-13 Johns Hopkins University Method and products for delivering biological molecules to cells using multicomponent nanostructures
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
GB0316912D0 (en) 2003-07-18 2003-08-20 Oxford Instr Superconductivity Therapeutic treatment
US20050031544A1 (en) * 2003-08-07 2005-02-10 Njemanze Philip Chidi Receptor mediated nanoscale copolymer assemblies for diagnostic imaging and therapeutic management of hyperlipidemia and infectious diseases
WO2005019470A2 (en) * 2003-08-11 2005-03-03 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
DE10354361A1 (de) * 2003-11-20 2005-06-23 Eberhard-Karls-Universität Tübingen Vorrichtung zum Einbringen in mittels Kernspinresonanztomografie untersuchbares Körpergewebe
WO2005060610A2 (en) * 2003-12-11 2005-07-07 The Trustees Of Columbia University In The City Ofnew York Nano-sized particles, processes of making, compositions and uses thereof
WO2005076938A2 (en) * 2004-02-11 2005-08-25 Massachusetts Institute Of Technology Multi-polymer-coated magnetic nanoclusters
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
DE102004010387A1 (de) * 2004-03-03 2005-09-22 Siemens Ag Kontrastmittel für die Röntgen-Computertomographie
JP2005296942A (ja) * 2004-03-15 2005-10-27 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
WO2005087367A1 (ja) * 2004-03-15 2005-09-22 Hitachi Maxell, Ltd. 磁性複合粒子およびその製造方法
US7842281B2 (en) * 2004-05-10 2010-11-30 The Florida State University Research Foundation Magnetic particle composition for therapeutic hyperthermia
DE102004052533A1 (de) * 2004-10-15 2006-05-04 Mykhaylyk, Olga, Dr. Magnetische Partikel zur Verwendung in Therapie und Diagnostik
EP1805318B1 (en) 2004-10-27 2014-09-03 Cepheid Closed-system multi-stage nucleic acid amplification reactions
US7939267B2 (en) * 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
US20060140867A1 (en) * 2004-12-28 2006-06-29 Helfer Jeffrey L Coated stent assembly and coating materials
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
US7371738B2 (en) * 2005-04-15 2008-05-13 University Of South Florida Method of transdermal drug delivery using hyaluronic acid nanoparticles
EP1721603A1 (en) * 2005-05-11 2006-11-15 Albert-Ludwigs-Universität Freiburg Nanoparticles for bioconjugation
JP2008545665A (ja) * 2005-05-23 2008-12-18 ユニベルシテ ドゥ ジュネーブ 高体温による処置のための注入可能な超常磁性ナノ粒子および高体温インプラントを形成するための使用
US20060281104A1 (en) * 2005-06-13 2006-12-14 Macevicz Stephen C Leuco dye particles and uses thereof
KR100806669B1 (ko) * 2005-06-23 2008-02-26 김정환 나노 입자-생체 복합체
WO2007002732A1 (en) * 2005-06-28 2007-01-04 Joslin Diabetes Center, Inc. Methods of imaging inflammation in pancreatic islets
US20070009436A1 (en) * 2005-07-08 2007-01-11 Rondinone Adam J Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto
EP1743530B1 (en) * 2005-07-15 2011-08-31 Unilever N.V. Iron fortified food product and additive
CZ301067B6 (cs) * 2006-02-24 2009-10-29 Ústav makromolekulární chemie AV CR Superparamagnetické nanocástice na bázi oxidu železa s modifikovaným povrchem, zpusob jejich prípravy a použití
AU2007240758C1 (en) * 2006-04-21 2013-06-27 Drexel University Magnetic targeting and sequestering of therapeutic formulations
JP5282031B2 (ja) * 2006-05-15 2013-09-04 ドミトリィ ビー カーポティン 有機物を含む磁性微粒子
KR100827292B1 (ko) * 2006-05-30 2008-05-07 애니젠 주식회사 실리콘-포함 수용성 고분자로 코팅된 나노입자 및 그의조영제로서의 용도
US8119352B2 (en) * 2006-06-20 2012-02-21 Cepheld Multi-stage amplification reactions by control of sequence replication times
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
US20090297626A1 (en) * 2006-11-03 2009-12-03 The Trustees Of Columbia University In The City Of New York Methods for preparing metal oxides
PL2117600T3 (pl) * 2006-12-18 2013-05-31 Colorobbia Italiana Spa Magnetyczne nanocząsteczki do stosowania w hipertermii, ich wytwarzanie i zastosowanie w konstruktach o zastosowaniu farmakologicznym
BRPI0823269B8 (pt) 2007-01-21 2021-06-22 Hemoteq Ag cateter de balão
KR100809402B1 (ko) * 2007-01-29 2008-03-05 김정환 나노 입자 표지, 나노 입자 표지를 이용하는 진단 키트, 및진단 방법
US20080255425A1 (en) * 2007-04-13 2008-10-16 Ethicon Endo-Surgery, Inc. Nanoparticle treated medical devices
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
US20110311457A1 (en) * 2007-07-26 2011-12-22 Nanoscan Imaging, Llc Methods for imaging vascular inflammation using improved nanoparticle contrast agents
EP2022508A1 (en) * 2007-08-07 2009-02-11 Charité-Universitätsmedizin Berlin Production of targeted MRI probes by biocompatible coupling of macromolecules with charged nanoparticles
WO2009031859A2 (en) * 2007-09-06 2009-03-12 Anygen Co., Ltd. Multi-functional complex for imaging and drug delivery
EP2211910B1 (en) * 2007-11-07 2017-11-01 University Of Houston Ultrasmall superparamagnetic iron oxide nanoparticles and uses thereof
US20090157069A1 (en) * 2007-12-06 2009-06-18 Curtis Tom Systems and methods for thermal treatment of body tissue
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
JP2009256286A (ja) * 2008-04-21 2009-11-05 Fujifilm Corp 常磁性金属化合物含有ポリマー粒子
US20100018674A1 (en) * 2008-07-22 2010-01-28 Donald John Enzinna Reservoir with moveable partition for quick recovery
WO2010102065A1 (en) 2009-03-05 2010-09-10 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
US20120107229A1 (en) * 2009-04-15 2012-05-03 Xuefei Huang Novel nano-probes for molecular imaging and targeted therapy of diseases
US20100297745A1 (en) * 2009-05-19 2010-11-25 Nanyang Technological University Flow-through method of functionalizing inner surfaces of a microfluidic device
WO2011005421A2 (en) 2009-07-10 2011-01-13 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
US10080821B2 (en) * 2009-07-17 2018-09-25 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US20110054236A1 (en) * 2009-08-25 2011-03-03 The Regents Of The University Of Michigan Compositions and methods for targeting tumors
EP2322142B1 (de) * 2009-11-12 2016-07-27 Helmholtz-Zentrum Geesthacht Zentrum für Material- und Küstenforschung GmbH Biokompatible, magnetische Nanopartikel zur Behandlung von Glioblastomen
DE102009058769A1 (de) 2009-12-16 2011-06-22 MagForce Nanotechnologies AG, 10589 Temperaturabhängige Aktivierung von katalytischen Nukleinsäuren zur kontrollierten Wirkstofffreisetzung
US20110160645A1 (en) * 2009-12-31 2011-06-30 Boston Scientific Scimed, Inc. Cryo Activated Drug Delivery and Cutting Balloons
KR101057484B1 (ko) * 2010-03-19 2011-08-17 강원대학교산학협력단 소장의 조영을 위한 경구용 조영제
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
US8815294B2 (en) 2010-09-03 2014-08-26 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives and a carrier material
US9744235B2 (en) 2010-10-19 2017-08-29 The Board Of Regents Of The University Of Oklahoma Treatment of cardiovascular disorders with targeted nanoparticles
US10398668B2 (en) 2010-10-19 2019-09-03 The Board Of Regents Of The University Of Oklahoma Glutamate treatment of cardiovascular disorders
US8740872B2 (en) 2010-10-19 2014-06-03 The Board Of Regents Of The University Of Oklahoma Magnetically-targeted treatment for cardiac disorders
KR101297815B1 (ko) 2010-11-18 2013-09-03 충남대학교산학협력단 폴리감마글루탐산과 광학영상다이의 복합체를 함유하는 센티넬 림프노드 감지용 광학영상 프로브
US8197471B1 (en) * 2011-02-14 2012-06-12 Samuel Harry Tersigni Core-excited nanoparticles and methods of their use in the diagnosis and treatment of disease
WO2012110835A2 (en) 2011-02-15 2012-08-23 Semmelweis Egyetem Prussian blue based nanoparticle as multimodal imaging contrast material
KR101398214B1 (ko) * 2011-04-06 2014-05-23 주식회사 바이오리더스 음이온성 고분자와 양이온성 고분자 이온복합체 기반 고감도 자기공명영상 나노조영제 및 이의 제조방법
US9060938B2 (en) 2011-05-10 2015-06-23 Bend Research, Inc. Pharmaceutical compositions of active agents and cationic dextran polymer derivatives
US8669360B2 (en) 2011-08-05 2014-03-11 Boston Scientific Scimed, Inc. Methods of converting amorphous drug substance into crystalline form
US9056152B2 (en) 2011-08-25 2015-06-16 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
KR101301276B1 (ko) 2011-11-21 2013-08-29 주식회사 이노테라피 카테콜기가 결합된 키토산 또는 폴리아민 및 말단에 티올기가 결합된 폴락소머를 포함하는 하이드로젤 및 이의 제조방법 및 이를 이용한 지혈제
EP2647389A1 (en) 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
US8873041B1 (en) 2013-01-29 2014-10-28 Bayspec, Inc. Raman spectroscopy using multiple excitation wavelengths
US9987616B2 (en) 2013-02-27 2018-06-05 Empire Technology Development Llc Preparation and use of magnetic polymer nanocomposites
EP2823858A1 (en) * 2013-07-12 2015-01-14 Brossel, Rémy System generating a constraint field, and medical device implementing the same
US20150064107A1 (en) * 2013-09-04 2015-03-05 King's College London Imaging agent
DE102014106603A1 (de) 2014-05-12 2015-11-12 Verein zur Förderung von Innovationen durch Forschung, Entwicklung und Technologietransfer e.V. (Verein INNOVENT e.V.) Verfahren und Vorrichtung zur Abreicherung von zirkulierenden Tumorzellen aus einer Zellsuspension
US10059621B2 (en) * 2016-05-27 2018-08-28 Corning Incorporated Magnetizable glass ceramic composition and methods thereof
US20170342383A1 (en) 2016-05-27 2017-11-30 Corning Incorporated Lithium disilicate glass-ceramic compositions and methods thereof
CN111417601A (zh) 2017-11-28 2020-07-14 康宁股份有限公司 化学强化的生物活性玻璃陶瓷
CN111405913A (zh) 2017-11-28 2020-07-10 康宁股份有限公司 生物活性玻璃组合物和牙本质超敏性修复
EP3717427A1 (en) 2017-11-28 2020-10-07 Corning Incorporated High liquidus viscosity bioactive glass
WO2020174476A1 (en) * 2019-02-28 2020-09-03 Hadasit Medical Research Services And Development Ltd. Targeted magnetic vehicles and method of using the same
CN111330023B (zh) * 2020-03-23 2023-01-31 中国科学院宁波材料技术与工程研究所慈溪生物医学工程研究所 一种磁性纳米复合材料及其制备方法与应用
DE102020116859A1 (de) 2020-06-26 2021-12-30 Pharma Development Holding Gmbh Liposomen
CN112402389A (zh) * 2020-11-24 2021-02-26 常州欧法玛制药技术有限公司 一种唑吡坦双层渗透泵控释片及其制备方法
CN112870387B (zh) * 2021-02-26 2023-08-29 中山大学孙逸仙纪念医院 一种磁性纳米药物载体及其制备方法和应用
WO2023245000A2 (en) * 2022-06-13 2023-12-21 Russell Van De Casteele Methods for processing, enrichment, delivery, formulation, uptake and testing for supplements and pharmaceuticals

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5913521B2 (ja) * 1975-06-19 1984-03-30 メイトウサンギヨウ カブシキガイシヤ 磁性酸化鉄・デキストラン複合体の製造法
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4323056A (en) * 1980-05-19 1982-04-06 Corning Glass Works Radio frequency induced hyperthermia for tumor therapy
EP0093757A1 (en) * 1981-11-12 1983-11-16 Ulf SCHRÖDER Intravascularly administrable, magnetically responsive nanosphere or nanoparticle, a process for the production thereof, and the use thereof
SE8201972L (sv) * 1982-03-29 1983-09-30 Gambro Lundia Ab Magnetiskt paverkbara kristalliserade kolhydrat sferer eller partiklar att anvendas tillsammans med bioadsorberande material
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4735796A (en) * 1983-12-08 1988-04-05 Gordon Robert T Ferromagnetic, diamagnetic or paramagnetic particles useful in the diagnosis and treatment of disease
JPS59195161A (ja) * 1983-04-21 1984-11-06 Fujirebio Inc 磁性粒子及びその製造法
US4554088A (en) * 1983-05-12 1985-11-19 Advanced Magnetics Inc. Magnetic particles for use in separations
US5720939A (en) * 1985-08-15 1998-02-24 Nycomed Imaging As Method of contrast enhanced magnetic resonance imaging using magnetically responsive-particles
US4788281A (en) * 1984-01-04 1988-11-29 Tosoni Anthony L Dextran hexonic acid derivative, ferric hydroxide complex and method manufacture thereof
GB8408127D0 (en) * 1984-03-29 1984-05-10 Nyegaard & Co As Contrast agents
JPS60260463A (ja) * 1984-06-01 1985-12-23 松下電器産業株式会社 高密度酸化物焼結体の製造方法
SE454885B (sv) * 1984-10-19 1988-06-06 Exploaterings Ab Tbf Polymerbelagda partiklar med immobiliserade metalljoner pa sin yta jemte forfarande for framstellning derav
DE3577185D1 (de) * 1984-11-01 1990-05-23 Nycomed As Paramagnetische kontrastmittel fuer die anwendung in "in vivo" nmr-diagnostischen methoden und die herstellung davon.
KR880701111A (ko) * 1986-04-07 1988-07-25 제뜨랭 프랑쎄 토모 농도측정에 사용하기 위한 조성물
US5352432A (en) * 1986-07-03 1994-10-04 Advanced Magnetics, Inc. Hepatocyte specific composition and their use as diagnostic imaging agents
US4827945A (en) * 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
US5262176A (en) * 1986-07-03 1993-11-16 Advanced Magnetics, Inc. Synthesis of polysaccharide covered superparamagnetic oxide colloids
US5679323A (en) * 1986-07-03 1997-10-21 Advanced Magnetics, Inc. Hepatocyte-specific receptor-mediated endocytosis-type compositions
US4770183A (en) * 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
DE3709851A1 (de) * 1987-03-24 1988-10-06 Silica Gel Gmbh Adsorptions Te Nmr-diagnostische fluessigkeitszusammensetzungen
DE3729697A1 (de) * 1987-09-04 1989-03-23 Siemens Ag Verfahren zur herstellung von pressfaehigem granulat fuer die fertigung von oxidkeramischen produkten, insbesondere mangan-zink-ferriten
US5395688A (en) * 1987-10-26 1995-03-07 Baxter Diagnostics Inc. Magnetically responsive fluorescent polymer particles
WO1990001295A1 (en) * 1988-08-04 1990-02-22 Advanced Magnetics, Incorporated Receptor mediated endocytosis type mri contrast agents
JPH0678247B2 (ja) * 1988-10-04 1994-10-05 大塚製薬株式会社 Ｎｍｒ造影用鉄含有製剤
US5612019A (en) * 1988-12-19 1997-03-18 Gordon, Deceased; David Diagnosis and treatment of HIV viral infection using magnetic metal transferrin particles
US5393525A (en) * 1989-07-21 1995-02-28 Nycomed Imaging As Contrast medium comprising superparamagnetic or ferromagnetic particles capable of increasing viscosity after administration
JP2726520B2 (ja) * 1989-10-20 1998-03-11 名糖産業株式会社 有機磁性複合体
US5389377A (en) * 1989-12-22 1995-02-14 Molecular Bioquest, Inc. Solid care therapeutic compositions and methods for making same
US5368840A (en) * 1990-04-10 1994-11-29 Imarx Pharmaceutical Corp. Natural polymers as contrast media for magnetic resonance imaging
IL98744A0 (en) * 1990-07-06 1992-07-15 Gen Hospital Corp Method of studying biological tissue using monocrystalline particles
DK0525199T4 (da) * 1991-01-19 2004-06-01 Meito Sangyo Kk Sammensætning indeholdende ultrafine partikler af magnetisk metaloxid
US5370901A (en) * 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
DE4117782C2 (de) * 1991-05-28 1997-07-17 Diagnostikforschung Inst Nanokristalline magnetische Eisenoxid-Partikel, Verfahren zu ihrer Herstellung sowie diagnostische und/oder therapeutische Mittel
CA2089148C (en) * 1991-06-11 2003-08-05 Masakatsu Hasegawa Oxidized complex comprising water-soluble carboxypolysaccaride and magnetic iron oxide
JP3189154B2 (ja) * 1991-07-18 2001-07-16 東ソー株式会社 免疫測定用担体の製造方法
CA2137145A1 (en) * 1992-06-08 1993-12-23 Mark S. Chagnon Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
JP3337075B2 (ja) * 1992-08-05 2002-10-21 名糖産業株式会社 小粒子径水溶性カルボキシ多糖−磁性酸化鉄複合体
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US5349957A (en) * 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
DE4301871A1 (de) * 1993-01-13 1994-07-14 Diagnostikforschung Inst Neue Mittel zur Diagnose von Gefäßerkrankungen
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
EP0634174A1 (en) * 1993-07-13 1995-01-18 Takeda Chemical Industries, Ltd. Antianemic composition for veterinary use
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
DE4428851C2 (de) * 1994-08-04 2000-05-04 Diagnostikforschung Inst Eisen enthaltende Nanopartikel, ihre Herstellung und Anwendung in der Diagnostik und Therapie

Also Published As

Publication number Publication date
NO970468L (no) 1997-04-02
NO314785B1 (no) 2003-05-26
CA2195318C (en) 2002-11-12
AU2921095A (en) 1996-03-04
IL114713A0 (en) 1995-11-27
US20020141943A1 (en) 2002-10-03
CN1155844A (zh) 1997-07-30
WO1996004017A1 (de) 1996-02-15
DE4428851C2 (de) 2000-05-04
US6576221B1 (en) 2003-06-10
EP0773796A1 (de) 1997-05-21
KR970704476A (ko) 1997-09-06
HUT77993A (hu) 1999-04-28
AU703042B2 (en) 1999-03-11
KR100278513B1 (ko) 2001-01-15
NO970468D0 (no) 1997-02-03
DE4428851A1 (de) 1996-02-08
US6048515A (en) 2000-04-11
CN1103604C (zh) 2003-03-26
CA2195318A1 (en) 1996-02-15
JPH10503496A (ja) 1998-03-31
IL114713A (en) 2000-02-17

Similar Documents

Publication Publication Date Title
ZA956005B (en) Iron-containing nanoparticles their production and their use for diagnostic and therapeutic purposes
EP0711572A4 (en) INHALATOR AND METHOD FOR USE THEREOF
CY2508B1 (en) Benzopyrans and their use as therapeutic agents
IL110464A0 (en) Novel proteins for the diagnosis, imaging, and therapy of human cancer
EP0831793A4 (en) PROTEIN PARTICLES FOR THERAPEUTIC AND DIAGNOSTIC USE
GB9307754D0 (en) Diagnostic probes and therapeutic products
GB9419553D0 (en) Polypeptides and their use in the treatment of auto-immune disease
GB9425600D0 (en) Targeting complexes and use thereof
ZA976547B (en) Lipid-binding proteins and their therapeutic and diagnostic use
IL116134A0 (en) Iminooxybenzylcrotonate esters their preparation and their use
IL109540A0 (en) Synthetic peptides and their use in tumor diagnosis and therapy
GB9423702D0 (en) Diagnosis and treatment of tumours
GB9523066D0 (en) Compounds and their therapeutic use
GB9419906D0 (en) Bnezoic amide retinoids for use in the treatment of skin diseases and cancer
AU5279996A (en) Antibodies and their use in cancer therapy and diagnosis
ZA959204B (en) Oxazolidinedioe derivatives their production and use
GB9416930D0 (en) Dienes for use in the treatment of skin diseases and cancer
IL106658A0 (en) Cancer diagnosis and treatment
GB9520159D0 (en) Benzoioc amide retinoids for use in the treatment of skin diseases and cancer
GB9410669D0 (en) Diagnostic method and therapy
ZA948919B (en) Tetrazole derivatives their production and use
GB9621995D0 (en) Susceptibility to cancer:diagnosis and treatment thereof
GB9825610D0 (en) Combined rapid diagnosis and therapy
GB9926811D0 (en) Combined rapid diagnosis and therapy
GB9517072D0 (en) Dienes for use in the treatment of skin diseases and cancer